Protein kinase C (PKC) plays an important role in proliferation
and differentiation of mammalian cellsi:>. To search for specific inhibitors of PKC, we developed a unique assay system, named bleb-forming assay2J. In the course of our screening program, an inhibitor was isolated from a culture broth of a streptomycete and it was identified as sangivamycin which is known as an antifungal and antitumor antibiotic3). In previous papers4>5), the mechanism of action of sangivamycin was considered to be same as that of tubercidin and toyocamycin which have the same nucleoside skeleton, 7-deazaadenosine ( Fig.  1) . We found that the activity of sangivamycin was distinctly different from that of tubercidin and toyocamycin in our assay system. In this paper, we describe a unique biological activity of sangivamycin distinguishing it from tubercidin and toyocamycin. 
Materials and Methods
Cell Culture and Bleb-forming Assay K562, a humanchronic myelocytic leukemia cell6) was cultured in RPMI1640mediumsupple-mented with 10% fetal calf serum (GIBCO, Grand Island, NY, U.S.A.). Cells were seeded into a 96-multiwell plate at a density of 1 x 104 cells/well, incubated for 10 minutes at 37°C in a CO2 incubator, and then treated with phorbol 12,13-didecanoate (PDBu) at a final concentration of 1^g/ml. After 10 minutes incubation with PDBu, morphology of cell surface was observed under a microscope.
In Vitro Kinase Assay of PKC and Epidermal Growth Factor (EGF)-receptor PKCwas extracted from a rabbit brain and the extract was partially purified on a DEAE-cellulose column. The active fraction of PKC, eluted from DEAE-cellulose by 100 mMNaCl, was used for the assay as described in a previous paper2). EGF-receptor was prepared from the membraneof A431 cells by Thom's procedure70. Autophosphorylation of EGF-receptor was assayed as described by Carpenter et alP. The results of phosphorylation by both kinases were observed by autoradiography after electrophoresis of 32P-phosphorylated proteins on SDS-polyacrylamide gel0) ; histone was used for PKCassay as a substrate.
Chemicals
Sangivamycin was purified successively on Dowex 50, Dowex 1, silica gel, and by HPLC(Nucleosil 5C18, 40%MeOH).Our preparation was indistinguishable from authentic sangivamycin according to the following spectroscopic data: The UVabsorption spectrum 0*max 230 and 280 nm), high-resolution fast atom bombardment mass spectrometry (HRFAB-MS)((M+H)+ mjz 310.1 182, C12H16N5O5), and *H NMR. Tubercidin10) and toyocamycinn) were isolated and stored in our laboratory. 
Results
Suppression of Bleb-formation by Sangivamycin Blebs appeared within 10 minutes on the cell surface of K562 induced by 1^g/ml of PDBu (Fig.   2b ). Staurosporine which is knownas a strong inhibitor of PKC12) inhibited the bleb-formation induced by PDBuat the concentration of 1 /*g/ml (Fig. 2c) . We have isolated an inhibitor ofblebformation from a culture filtrate of a streptomycete and identified it as sangivamycin. Purified sangivamycin completely suppressed blebformation at the concentration of 30^g/ml (Fig.  2f) . In contrast, 100^g/ml of tubercidin and toyocamycin did not suppress the bleb-formation (Figs. 2d and 2e ).
Inhibition of In Vitro Kinase Activity of PKC
Bleb-formation on K562 cell surface seemed to be closely related with the activity of PKC. Because we have shown2) that suppressors of bleb-formation {i.e. staurosporine, H7 which is an isoquinoline derivative and some isoflavones) inhibit PKCactivity, the inhibitory activity of 7-deazaadenosine antibiotics against PKCwas tested in vitro. Even at the concentration of 10 g/ml, tubercidin did not inhibit phosphorylation ofhistone (Fig. 3a, lanes 3~6 ). In the case of toyocamycin, it showed no effect on PKCat (Fig. 3a, lanes 8~10 ). In contrast, sangivamycin inhibited PKC activity at the concentration of 0.3^g/ml. This inhibition was almost equal to that shown by toyocamycin at the concentration of 10^g/ml. These results are consistent with our previous observation on the correlation between the suppression of bleb-formation and inhibition of PKCactivity.
Inhibition of Autophosphorylation of EGF-receptor
PKCphosphorylates serine/threonine of proteins and its activity was inhibited by sangivamycin. As EGF-receptor is known to be a tyrosine-specific protein kinase, the inhibitory activity by sangivamycin for EGF-receptor was tested. Autophosphorylation of EGF-receptor is enhanced by the addition of EGF(5 ng/ml), therefore this inhibition experiment was carried out in presence of EGF. Tubercidin and toyocamycin showed weak inhibitory activity against autophosphorylation in a dosedependent manner (Fig. 3b, lanes 3~10 ). Sangivamycin showed strong inhibition against tyrosine kinase activity: It was more than 10-fold as strong as the other two antibiotics (Fig. 3b, lanes ll~14) . Sangivamycin inhibited the in vitro activity of PKCat a lower concentration than that required for tyrosine kinase activity of EGF-receptor.
Discussion
Sangivamycin is one of the three 7-deazaadenosine antibiotics produced in streptomycetes. Previous papers4'5-150 discussed the mechanism of action of deazaadenosine antibiotics. According to these papers, it was suggested that these antibiotics were phosphorylated in the target cell and incorporated into RNAas ATPanalogs, resulting in the inhibition of RNAand protein syntheses. From this point of view, there is no difference between these antibiotics. Actually, we observed that sangivamycin inhibited protein and RNAsyntheses of HL60 cells (a human promyelocytic leukemia cell) by pulse label experiments (data not shown).
However, the observation reported here suggests that the inhibition of protein kinases is an important activity of sangivamycin, because it inhibits very rapidly (10 minutes) bleb-formation induced by PDBu. Sangivamycin showed an activity distinct from that of other deazaadenosine antibiotics, tubercidin and toyocamycin. Comparedwith the other two antibiotics which show strong antibacterial and antifungal activities, sangivamycin only shows a weak antimicrobial activity13).
7-Deazaadenosineskeleton is common to the three antibiotics and maymimica part of ATP which is a substrate of protein kinases. Therefore, the antibiotic maybe able to inhibit kinase activities of PKCand EGF-receptor competing with ATP. However, the deazaadenosine skeleton is not sufficient to inhibit PKCactivity, because tubercidin and toyocamycin showed only slight inhibitory effect on bleb-formation of K562cells and in vitro PKCactivity. It was concluded that the carbamoyl group on C-7 of the 7-deazaadenosine skeleton is important to suppress bleb-formation induced by PDBu and to inhibit PKC activity.
Wealso observed that incorporation of [3H]thymidine into quiescent mammalian cells induced by EGF was blocked by sangivamycin (details will be published elsewhere). These data indicate that sangivamycin will prove to be a useful tool for studying ATP-related reactions in cells. Originally, sangivamycin was discovered as an antitumor agent3), and now the antibiotic was shownto inhibit PKC. However, the direct relationship between antitumor activity and the inhibitory activity of
PKCis not yet known. The present study suggests that the screening of potent inhibitors of PKCmay provide possible antitumor agents. It is worth testing whether sangivamycin inhibits tumor-promotioninvivo.
It is to be noted that the findings described in this paper were obtained as the results of our screening for PKC inhibitors from microbial secondary metabolites. After publishing these results14), we found a paper by Loomis and Bell describing the mode of action of sangivamycin15). They tested several knownantitumor nucleoside compoundsfor inhibition of PKCand found that sangivamycin showed the strongest inhibitory activity among the nucleosides tested. They calculated Ki between sangivamycin and PKCas 10 //m (ca. 3 //g/ml); this value is comparable to our result shown in Fig. 3a .
